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Background: Sociodemographic factors, alcohol and drug intake, and maternal health 
are known to be associated with adverse outcomes in pregnancy for women with 
severe mental illness in addition to their use of psychotropic medication. In this study, 
we describe the demographic characteristics of women hospitalized for severe mental 
illness along with their use of medication and other drugs during the pregnancy period.
Methods: A clinical case note review of women with psychosis who were hospitalized at 
the State Psychiatric Hospital in Western Australia during 1966–1996, gave birth between 
1980 and 1992, and received psychiatric treatment during the pregnancy period. The 
mother’s clinical information was available from the case notes and the midwives record. 
The demographic characteristics of the mothers were described together with their 
hospitalization pattern and their medication and substance use during the pregnancy 
period.
results: A total of 428 mothers with a history of severe mental illness were identified 
who gave birth during 1980–1992. Of these, 164 mothers received psychiatric care 
during the pregnancy period. One hundred thirty-two had taken psychotropic medi-
cation during this period. Mothers who were married, of aboriginal status or living in 
regional and remote areas appeared less likely to be hospitalized during the pregnancy 
period, while older mothers and those with a diagnosis of schizophrenia were more likely 
to be hospitalized. The number of mothers taking psychotropic medication in the first 
trimester of pregnancy was reduced compared to the previous 6 months. The decline 
in the number taking substances over the same period was not significant. In all, 16% 
of the women attempted suicide during the pregnancy period and 10% non-suicidal 
self-injury.
conclusion: The women demonstrate a pattern of decreased use of psychotropic 
medication use from the period before pregnancy to the first trimester of pregnancy. 
Our data highlight the importance of women with severe mental illness receiving regular 
ongoing monitoring and support from their psychiatrist during pregnancy regarding the 
level of medication required as well as counseling with regard to substance use, non-sui-
cidal self-injury, and attempted suicide.
Keywords: mental illness, pregnancy, demographic factors, hospitalization, psychotropic medication, medical 
record linkage
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inTrODUcTiOn
Sociodemographic factors (1), alcohol and drug intake (2–4), use 
of psychotropic medication, and untreated disease, which may 
be exacerbated or recur during pregnancy, have been shown to 
be associated with adverse outcomes in pregnancy for women 
with severe mental illness (5–11). Here, we report on a small case-
comparison study where data on medication and drug intake, 
attempted suicide, and non-suicidal self-injury was available 
for women who had received psychiatric care for severe mental 
illness during their pregnancy period. Our aims were to describe 
the demographic characteristics of women hospitalized for severe 
mental illness along with their pattern of hospitalization and their 
use of medication and other drugs during the pregnancy period. 
For the purposes of this study, the pregnancy period is defined 
as commencing 6  months prior to pregnancy until the end of 
pregnancy.
MaTerials anD MeThODs
Women with a diagnosis of schizophrenia, bipolar disorder, or 
unipolar major depression who were treated at the State Psychiatric 
Hospital of Western Australia between 1966 and 1996 and gave 
birth between 1980 and 1992 were identified via linkage of the 
WA Midwives Notification System and the WA Mental Health 
Information System (MHIS). Further information was collected 
by clinical case note review for the women who were treated by 
psychiatric inpatient or outpatient services during the pregnancy 
period. The study focuses on this subgroup of women.
The study had University of Western Australia Human 
Research Ethics Committee approval as well as specific approv-
als from the individual inpatient and outpatient mental health 
services at which the clinical records were held. The data were 
analyzed using SAS version 9.4 (SAS institute Inc., Cary, NC, 
USA).
The International Classification of Diseases, ninth Revision 
codes (12) were used to identify specific disorders: schizophrenia 
(295.0–295.9), bipolar disorder (296.0, 296.2–296.5), and unipo-
lar major depression (296.1, 296.6, 296.8, 296.9). The concurrent 
validity of MHIS ICD-9 diagnoses had been ascertained against 
an independent case sample assessed using a semi-structured 
diagnostic interview (13), which established sensitivity of 0.92 
and specificity of 0.88 for schizophrenia and 0.80 and 0.90, 
respectively, for affective disorders (14). The clinical case note 
review was undertaken by two of the coauthors (John Dean and 
Jenny Griffith) using structured checklists developed specifically 
for this study to collect information on medications, substance 
use, attempted suicide, non-suicidal self-injury, and other clini-
cal and risk data for the women who were treated by psychiatric 
inpatient or outpatient services during the pregnancy period. 
If the women had attended other hospitals/outpatient services 
in addition to the State Psychiatric Hospital, medical records 
from these sites were also retrieved where possible. Women 
were recorded as having used psychotropic medication and/or 
substances according to the trimester of pregnancy or prepreg-
nancy period, if this was recorded in their medical record while 
they were being treated, either as an inpatient or an outpatient. 
Variables were created for each trimester and for each group of 
psychotropic medications to indicate whether or not the women 
were recorded as using the medication during that period of time. 
Psychotropic medications recorded included typical antipsychot-
ics, tricyclic antidepressants, mood stabilizers, benzodiazepines, 
and hypnotics. Substances recorded included alcohol, cannabis 
and other.
No further information was collected for the women who 
did not receive psychiatric inpatient or outpatient care during 
the study, but their demographic information was available for 
comparison with those who did receive psychiatric care.
Demographic and clinical information was compared for all 
mothers included in the study, those receiving psychiatric care 
during their pregnancy period and those receiving psychiatric 
care and who took medication during the pregnancy period. 
For comparison of demographic characteristics, socioeconomic 
status was measured using the Australian Bureau of Statistics 
Socioeconomic Indices for Areas—index of relative disadvan-
tage (15) and accessibility/remoteness was measured using the 
ARIA + index (16). Variation in demographic characteristics of 
mothers for all births and for those admitted to hospital was con-
ducted using a binomial test for differences between proportions.
The number of births where the mother was hospitalized 
voluntarily with a psychiatric diagnosis was calculated as was the 
average length of stay per birth in days for these admissions. This 
was repeated for involuntary admissions.
The number of mothers taking psychotropic medication 
and substances was calculated for the 6-month period before 
pregnancy and for each trimester. Whether or not there was a sig-
nificant change in the proportion of women taking medication or 
substances prepregnancy and in the first trimester of pregnancy 
and then between the first and second trimester and the second 
and third trimester was tested using a t-test for paired samples.
resUlTs
The selection of the 428 mothers into the study is illustrated in 
Figure 1.
The demographic characteristics of the mother relating to each 
birth are shown in Table 1. This shows that of the three diagnostic 
groups included in the study, mothers with schizophrenia were 
most likely to receive psychiatric care during the pregnancy 
period and those with unipolar depression were least likely to 
receive treatment. A lower proportion of those who were mar-
ried or in a de facto relationship were in the group who were 
hospitalized compared to those who were single, divorced, or 
separated. The proportions of aboriginal mothers and those living 
in regional and remote areas were also lower in the hospitalized 
group. Mothers aged over 34  years appeared more likely to be 
hospitalized than their younger counterparts, as were those living 
in the city. Parity and low socioeconomic status appeared to have 
little effect on the risk of hospitalization during the pregnancy 
period. Table 2 shows hospital admission data for each mother 
during the pregnancy period. This was a group of mothers at high 
risk for suicide and non-suicidal self-injury as indicated by 24 
suicide attempts by 22 of the mothers (a suicide attempt in 14.6% 
of pregnancy periods) and 15 cases of non-suicidal self-injury by 
FigUre 1 | selection of patients in the study.
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14 mothers (9%) during the pregnancy period. Thirteen of the 
mothers had an intellectual disability (8%).
Table 3 shows medication intake, alcohol, and substance abuse 
across the pregnancy period. The number of mothers taking psy-
chotropic medication was significantly reduced when the period 
6 months before pregnancy was compared with the first trimester 
but there were no further significant changes in the following 
trimesters. Typical antipsychotics were the most common form 
of medication consumed. The medications prescribed for these 
mothers while they were in hospital included typical antipsychot-
ics, tricyclic antidepressants, mood stabilizers, benzodiazepines, 
and hypnotics. Selective serotonin reuptake inhibitors (SSRIs) 
and Reversible Monoamine Oxidase Inhibitor Antidepressants 
were not available during the period of the study (17). The 
number of mothers using substances, which were mainly alcohol 
and cannabis, appeared to show a decline from the prepregnancy 
period to the end of the pregnancy. However, further inspection 
of the data indicates that the mothers using substances during 
the prepregnancy period were a different group to those using 
substances during pregnancy.
DiscUssiOn
In this descriptive study, we have documented the sociodemo-
graphic circumstances and the use of psychotropic medication 
and substances during pregnancy for women with severe mental 
illness who received psychiatric inpatient or outpatient services 
during the pregnancy period.
TaBle 2 | Mothers’ hospital admission profile during the pregnancy 
period for 164 births where the mother received inpatient or outpatient 
psychiatric treatment during the pregnancy period.a
category of birth number 
of births
average 
length 
of stay 
per 
birth 
(days)
average 
no. of 
admissions 
per birth
Births involving any psychiatric 
hospitalization of mother during pregnancy 
period
119 
(73%)
37 2.1
Births involving any psychiatric 
hospitalization of mother during pregnancy 
period and mother taking psychotropic 
medication
104 
(83% of 
119)
37 1.9
Births involving involuntary hospitalization of 
mother during pregnancy period
60 (37%) 36 1.4
Births involving involuntary hospitalization 
of mother during pregnancy period and 
mother taking psychotropic medication
51 (85% 
of 60)
36 1.4
aMothers who gave birth during 1980–1992 and had also been an inpatient at the State 
Psychiatric Hospital during 1966–1996.
TaBle 1 | Demographic characteristics of mother for each birth.a
Demographic variable all births—status 
of mother
Births to mothers 
receiving 
psychiatric 
treatment during 
the pregnancy 
period—cases
Births to mothers 
not receiving 
psychiatric 
treatment during 
the pregnancy 
period—
comparison
Births to mothers receiving psychiatric 
treatment and who took medication during the 
pregnancy period (subset of cases)
N % of total N % of total N % of total N % of those admitted during pregnancy period
No. of births 704 100 164 23 540 77 132 80
No. of mothers 428 100 138 32 290 68 113 82
Parity
1 428 61 104 63 324 60 87 66
2 207 29 47 29 160 30 35 27
3+ 69 10 13 8 56 10 10 7
Diagnosis
Schizophrenia 293 42 84 51* 209 39 69 52
Bipolar disorder 317 45 68 42 249 46 56 43
Unipolar depression 94 13 12 7* 82 15 7 5
age group
≤19 years 50 7 8 5 42 8 6 5
20–34 years 584 83 133 81 451 83 107 81
≥35 years 70 10 23 14* 47 9 19 14
Marital status
Married/de facto 505 72 99 60* 406 75 67 61
Single/divorced/separated 199 28 65 40* 134 25 46 39
Aboriginality 70 10 7 4* 63 12 5 4
SES (bottom 20th percentile) 216 31 52 32 164 31 46 35
aria
City 456 65 131 80* 325 61 108 82
Regional 151 31 22 13* 129 24 16 12
Remote 91 4 11 7 80 15 8 6
aMothers who gave birth during 1980–1992 and had also been an inpatient at the State Psychiatric Hospital during 1966–1996.
*p < 0.05 significant difference between births exposed to and births not exposed to psychiatric treatment during the pregnancy period.
SES, socioeconomic status measured as SEIFA, socioeconomic indices for areas (15).
ARIA, accessibility remoteness index of Australia (16).
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Medication Use
The majority of the women who were hospitalized took psycho-
tropic medication (80%), which is indicative of the severity of the 
disease, with antipsychotics recorded as the dominant medication 
category (73%) followed by mood stabilizers (21%), anxiolytic/
hypnotics (16%), antidepressants (12%), and benzodiazepines 
(9%). Our data show fewer women taking medication during 
pregnancy than in the period immediately before pregnancy. This 
may be because the women are concerned about the potential 
effect of their medication on the developing fetus (18), or on the 
recommendation of their clinician, or because the severity of 
their illness declined during pregnancy. This finding of a decline 
in use is supported by a study by Toh et al. of 585,615 deliveries 
in the US to women aged 15–45  years during 2001–2007. Toh 
et  al. found that 4,223 (0.72%) of the women were exposed to 
atypical antipsychotics and 548 to typical antipsychotics (0.09%) 
any time from 60 days before pregnancy until delivery (19). Of 
the women in Toh’s study taking atypical antipsychotics, the most 
common diagnosis was depression (63%) followed by bipolar 
disorder (43%) and schizophrenia (13%). Some 0.5% of women 
filled a prescription for atypical antipsychotics during the first 
TaBle 3 | Medication intake and substance use by pregnancy period.
Medication type 6 months 
before 
pregnancy
Trimester 1 Trimester 2 Trimester 3 Total
N = 158 % N = 149 % N = 149 % N = 152 % N = 164 %
Any medication 87 55 44** 30 53 36 53 35 132 80
Typical antipsychotic 79 50 36** 24 47 32 43 28 119 73
Antidepressant (not SSRI, RIMA) 12 8 4* 3 3 2 4 3 19 12
Mood stabilizer 24 15 9** 6 9 6 13 9 34 21
Benzodiazepine and anxiolytic/hypnotics 27 17 6** 4 6 4 11 7 39 24
Substance abuse (including alcohol and cannabis) 14 9 9 6 9 6 3 2 28 17
Alcohol abuse 9 6 5 3 6 4 3 2 18 11
Cannabis abuse 6 4 6 4 5 3 1 1 15 9
*p < 0.01, **p < 0.001 significant difference between value 6 months before pregnancy and at trimester 1.
SSRI, selective serotonin reuptake inhibitor; RIMA, reversible inhibitors of monoamine oxidase A.
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trimester, 0.3% in the second trimester, and 0.2% in the third 
trimester. As with atypical antipsychotics, the prevalence of typi-
cal antipsychotic usage was greatest during the first trimester and 
then dropped in the last two semesters.
A similar study in Germany (2) on a cohort of 41,293 women 
who gave birth between June 2000 and May 2001 showed decreas-
ing prescription rates from the period before pregnancy to the 
end of the pregnancy for antidepressants and antipsychotics, as 
did a Swedish study (4). Studies on the use of antidepressants 
during pregnancy indicate that the strongest decline in use is seen 
after the first trimester (3).
substance Use
Psychotic illness is a known risk factor for substance use (20, 21). 
Nine percent of those hospitalized in our study were recorded as 
using substances while pregnant. Five and a half percent of those 
hospitalized also used alcohol while pregnant. This compares with 
data from the United States (22) in 2002–2003, which showed 
that 4.7% of pregnant women reported any illicit substance use 
in the previous 30 days and 10% reported similar alcohol use. The 
comparable rate of alcohol consumption in non-pregnant women 
was 53.0%. Use of any substance including cigarettes was 63.9% in 
non-pregnant women and 25.8% in pregnant women. The study 
(22) reported reduced use of substances in the second and third 
trimesters as opposed to the first trimester and that the odds ratio 
for recent substance abuse among those with possible current 
psychopathology was 2.83. It is likely that the level of substance 
abuse is underreported in our study as it has only been recorded 
when the mother was in hospital.
suicide and non-suicidal self-injury
The risk of suicide and non-suicidal self-injury are reduced dur-
ing pregnancy in the general population (23, 24). As we do not 
have data for before and after pregnancy in our study, it is not pos-
sible to see whether our results were significantly lower or higher 
during pregnancy. This is an area requiring further research.
Demography
The demographic profile of the women shows little difference 
between those taking and not taking psychotropic medication. 
Differences between those receiving and not receiving treatment, 
however, may be associated with the location of the Statewide 
psychiatric hospital, which is in the metropolitan area and thus 
less accessible to those from regional and remote areas. As the 
majority of the aboriginal population live in rural and remote 
areas, this is likely to be why aboriginal mothers have a lower 
treatment rate. Higher treatment rates for single mothers are likely 
to be associated with a low level of support available at home (25). 
The higher admission rate for older mothers is consistent with 
the higher admission rate seen in women aged 35–44 for mental 
illness (26).
advantages and limitations of This study
There are a number of potential limitations to this study. The 
data are from the period 1980–1992 when the newer forms of 
antipsychotics and antidepressants were not widely available: 
atypical antipsychotics and SSRIs were introduced in the early 
nineties (17). Data were collected on substance use but this did 
not include smoking despite its documented association with 
negative pregnancy outcomes. It is likely that substance use 
has been underreported, particularly in lighter users, due to its 
social undesirability. This would result in bias toward the null 
hypothesis. The strength of the study comes from its methodol-
ogy which combines record linkage to administrative midwives 
and psychiatric records with case notes review. This, in turn, has 
ensured that detailed information is available for each case, that 
the study is not reliant on retrospective recall and that the results 
are still relevant to current practice. Moreover, despite the small 
sample size, we have also been able to document a reduction 
in medication use during the pregnancy period compared to 
6 months before pregnancy.
cOnclUsiOn
This study on a cohort of 428 women of whom 164 received 
inpatient or outpatient psychiatric care for severe mental ill-
ness during the course of their pregnancy found that despite 
the severity of their illness, the women demonstrate a pattern 
of decreased use of psychotropic medication use from the 
period before pregnancy to the first trimester of pregnancy. 
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Our study cannot provide data on the reason for this change, 
but we speculate that it may reflect motivation by the treating 
clinician, the mother, or both to maximize outcomes for the 
babies. However, of note, recently published clinical guidelines 
(27) for the management of schizophrenia and related disorders 
highlight the lack of evidence-based information about the 
safety of antipsychotic medicines during pregnancy. These data 
are essential to inform medication management for women 
with severe mental illness during pregnancy, and much more 
research in this area is warranted to optimize benefits for both 
mother and child. These results highlight the importance of 
women with severe mental illness receiving regular ongoing 
monitoring and support from their psychiatrist during preg-
nancy regarding the level of medication required, substance 
use, and with regard to non-suicidal self-injury and attempted 
suicide.
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